CAV1 and metabolic dysfunction-associated steatotic liver disease: To further investigate CAV1's involvement in the progression of MASLD, we administered CSD (4.0 mg/kg body weight) chronically to HFD-fed mice daily for 4 weeks (Fig. 7A).